
https://www.science.org/content/blog-post/smugness-warning-sign
# Smugness as a Warning Sign (February 2012)

## 1. SUMMARY
The article discusses venture capitalist Bob More's advice to "never back smug" when evaluating people and companies in the biotech industry. The author notes that while developing innovative drugs requires strong egos, high intelligence, and stamina, these traits often spill over into problematic smugness and arrogance. The piece highlights how the life sciences industry has its share of "spinmeisters, hypesters, and smoke-and-mirrors actors" who display excessive confidence. The author argues this attitude is particularly dangerous in science because while any given person may indeed know something others don't, this must be viewed against the vast background of what we don't know. The article warns that smug attitudes drive away smart, competent, and motivated people who won't tolerate dismissive behavior like "You don't have to know about that" or "Oh, you probably wouldn't understand."

## 2. HISTORY
The issue of smugness and overconfidence in biotech leadership has manifested in several high-profile failures and scandals since 2012:

**Theranos (2012-2018)**: This represents perhaps the most extreme example of the dangers highlighted in the article. Elizabeth Holmes cultivated an image of revolutionary innovation in blood testing while maintaining secrecy through dismissive responses to legitimate questions. The company's collapse in 2018 after revelations of fraudulent technology validated the article's warning about "smoke-and-mirrors actors."

**Drug Development Failures**: Numerous biotech companies in the 2012-2020 period experienced significant stock crashes following overhyped clinical trial results that failed to deliver. Examples include Sarepta Therapeutics' controversial FDA approval process, various Alzheimer's drug failures despite optimistic projections, and immuno-oncology companies that promised revolutionary breakthroughs but delivered incremental benefits.

**Shifting Venture Capital Patterns**: Post-2012, venture capital in biotech has shown increasing skepticism toward charismatic leaders without strong scientific backing. The rise of data-driven due diligence and demands for reproducible results reflects the industry learning from the "never back smug" principle.

**Cultural Changes in Biotech**: The years following 2012 saw increased emphasis on transparency, data sharing, and collaborative approaches in drug development, partly as a reaction against the "lone genius" model that often accompanied problematic smugness.

## 3. PREDICTIONS
The article was more cautionary than predictive, but its underlying warning proved prescient:

• **Implicit Prediction**: That smug attitudes would lead to driving away valuable collaborators and eventual failure
  - **Outcome**: Validated by multiple high-profile failures where dismissive leadership cultures preceded scientific or business collapse

• **Implicit Prediction**: That the life sciences industry needed to guard against "spinmeisters" and "hypesters"
  - **Outcome**: Confirmed by major scandals and increased industry emphasis on data-driven validation over charismatic presentation

• **Implicit Prediction**: That arrogance rooted in partial knowledge while ignoring vast unknowns would prove dangerous
  - **Outcome**: Supported by numerous cases where companies failed because leadership couldn't acknowledge the limits of their knowledge

## 4. INTEREST
Rating: **7/10**
This article demonstrates lasting relevance by identifying a cultural vulnerability in biotech that has repeatedly manifested in high-profile failures and scandals over the subsequent decade, making it more insightful than typical industry commentary.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20120201-smugness-warning-sign.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_